NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free SLN Stock Alerts $21.62 -0.65 (-2.92%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$21.52▼$22.3050-Day Range$20.66▼$26.2552-Week Range$4.60▼$27.72Volume324,153 shsAverage Volume235,408 shsMarket Capitalization$647.09 millionP/E RatioN/ADividend YieldN/APrice Target$57.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Silence Therapeutics alerts: Email Address Silence Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside164.8% Upside$57.25 Price TargetShort InterestHealthy0.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.05Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.38) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.82 out of 5 starsMedical Sector537th out of 907 stocksPharmaceutical Preparations Industry244th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.49% of the outstanding shares of Silence Therapeutics have been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 10.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLN. Previous Next 1.6 News and Social Media Coverage News SentimentSilence Therapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Silence Therapeutics this week, compared to 1 article on an average week.Search Interest8 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -14.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -14.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 30.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Silence Therapeutics Stock (NASDAQ:SLN)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLN Stock News HeadlinesApril 23, 2024 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Given "Overweight" Rating at Morgan StanleyApril 13, 2024 | yahoo.comA youth's call to action on this Day of NO SilenceApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024April 8, 2024 | businesswire.comSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)April 1, 2024 | yahoo.comThe Lady of Silence: The Mataviejitas Murders Streaming: Watch & Stream Online via NetflixMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comAnalysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest ResultsApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 15, 2024 | seekingalpha.comSilence Therapeutics plc (SLN) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comSilence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | yahoo.comLocal authors 'Break the Silence' with book anthology to share the stories of survivorsMarch 13, 2024 | sg.finance.yahoo.comSingTel looking to sell significant Optus stake to Brookfield - sourceMarch 13, 2024 | seekingalpha.comSilence Therapeutics plc 2023 Q4 - Results - Earnings Call PresentationMarch 13, 2024 | businesswire.comSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 13, 2024 | businesswire.comSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)March 12, 2024 | markets.businessinsider.comSilence Therapeutics earnings: here's what Wall Street expectsFebruary 28, 2024 | finance.yahoo.comSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024February 28, 2024 | businesswire.comSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024February 24, 2024 | seekingalpha.comSilence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A LookFebruary 23, 2024 | businesswire.comSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)February 16, 2024 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?February 12, 2024 | investing.comSilence Therapeutics PLC (SLN)February 5, 2024 | finance.yahoo.comSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNovember 27, 2023 | markets.businessinsider.comSolid Financial Status and Promising Clinical Trial Results Drive Buy Rating for Silence TherapeuticsNovember 27, 2023 | finance.yahoo.comSilence Therapeutics plc's (NASDAQ:SLN) 65% Price Boost Is Out Of Tune With RevenuesSee More Headlines Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/25/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees109Year Founded1999Price Target and Rating Average Stock Price Target$57.25 High Stock Price Target$75.00 Low Stock Price Target$42.00 Potential Upside/Downside+164.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,820,000.00 Net Margins-171.41% Pretax Margin-198.27% Return on Equity-262.17% Return on Assets-45.62% Debt Debt-to-Equity Ratio0.01 Current Ratio4.56 Quick Ratio4.56 Sales & Book Value Annual Sales$31.55 million Price / Sales20.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book30.45Miscellaneous Outstanding Shares29,930,000Free Float29,045,000Market Cap$647.09 million OptionableNot Optionable Beta1.41 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.46MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $888.74kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $649.14kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABEvolusNASDAQ:EOLSBicycle TherapeuticsNASDAQ:BCYCCogent BiosciencesNASDAQ:COGTDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInstitutional OwnershipVivo Capital LLCBought 595,250 shares on 4/22/2024Ownership: 3.694%Parkman Healthcare Partners LLCBought 40,063 shares on 2/15/2024Ownership: 0.778%Cantor Fitzgerald L. P.Sold 21,416 shares on 2/15/2024Ownership: 0.490%Vivo Capital LLCBought 510,204 shares on 2/7/2024Ownership: 1.705%View All Institutional Transactions SLN Stock Analysis - Frequently Asked Questions Should I buy or sell Silence Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLN shares. View SLN analyst ratings or view top-rated stocks. What is Silence Therapeutics' stock price target for 2024? 4 analysts have issued 1-year price targets for Silence Therapeutics' stock. Their SLN share price targets range from $42.00 to $75.00. On average, they predict the company's stock price to reach $57.25 in the next twelve months. This suggests a possible upside of 164.8% from the stock's current price. View analysts price targets for SLN or view top-rated stocks among Wall Street analysts. How have SLN shares performed in 2024? Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN shares have increased by 24.5% and is now trading at $21.62. View the best growth stocks for 2024 here. Are investors shorting Silence Therapeutics? Silence Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 162,000 shares, an increase of 74.8% from the March 15th total of 92,700 shares. Based on an average trading volume of 241,700 shares, the days-to-cover ratio is currently 0.7 days. View Silence Therapeutics' Short Interest. When is Silence Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our SLN earnings forecast. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) announced its earnings results on Wednesday, March, 13th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.22. The firm had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Silence Therapeutics had a negative net margin of 171.41% and a negative trailing twelve-month return on equity of 262.17%. What ETFs hold Silence Therapeutics' stock? ETFs with the largest weight of Silence Therapeutics (NASDAQ:SLN) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS). Who are Silence Therapeutics' major shareholders? Silence Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (3.69%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
